Of these six subtypes, we observed that both luminal A and luminal B present lower CCL2 expression levels, whereas basal-like, HER2 positive, normal-like, and unclassified breast cancer exhibit higher CCL2 expression levels (p < 0.00001, Supplementary Figure S1A—upper row). Here, ERBB2 is linked to breast carcinoma.